Skip to main content
Clinical Trials/NCT02721147
NCT02721147
Completed
N/A

Pilot Study of an Intimacy Enhancement Intervention for Couples Facing Breast Cancer

Fox Chase Cancer Center1 site in 1 country89 target enrollmentOctober 27, 2015
ConditionsBreast Cancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Fox Chase Cancer Center
Enrollment
89
Locations
1
Primary Endpoint
Feasibility of the Treatment as Measured Through Study Accrual
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The central goal of this study is to examine the feasibility, acceptability, and preliminary efficacy of the IE intervention on patient and partner sexual QOL and relationship outcomes, and on patient psychosocial outcomes. We expect that the IE will show adequate feasibility, acceptability, and preliminary efficacy. Secondarily, based on the rationale that barriers exist that limit participation in intensive sexual QOL interventions for breast cancer survivors, an innovative secondary aim will investigate the perspectives of study-eligible patient candidates who opt out of participating in the pilot trial. We expect that we will be able to identify the participation barriers and intervention preferences of breast cancer survivors with sexual concerns who opt out of the intensive trial in order to inform the development of different interventions for future study.

Registry
clinicaltrials.gov
Start Date
October 27, 2015
End Date
September 29, 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age \> 21 years
  • Has diagnosis of non-recurrent stage I-III breast cancer
  • Completed active treatment (e.g., chemotherapy, radiation therapy, surgery) 6 months-5 years ago (current use of endocrine therapy is acceptable)
  • Has a partner or spouse who is \> 21
  • Lives with a romantic partner \> 6 months
  • Score of \> 3 on Patient Care Monitor Sexual Concerns screening item
  • No hearing impairment in patient or partner

Exclusion Criteria

  • Not able to speak English, as stated in medical record or as observed by study team member
  • ECOG Performance score \> 2 OR too ill to participate as judged by physician/in medical record
  • Overt cognitive dysfunction or psychiatric disturbance such as suicidal ideation or severe mental illness, as observed or judged by the researcher, referring source, or other qualified observer.
  • Past history of any cancer other than non-melanoma skin cancer
  • Currently participating in couple/marital therapy
  • Currently pregnant

Outcomes

Primary Outcomes

Feasibility of the Treatment as Measured Through Study Accrual

Time Frame: Up to 8 weeks

Feasibility is measured through the percentage of study eligible individuals who enrolled in the intervention study (i.e., acceptance rate).

Feasibility of the Treatment as Measured Through Study Attrition

Time Frame: Up to 8 weeks

Feasibility of treatment is measured through the number of randomized participants who completed the study.

Feasibility of the Treatment as Measured Through Session Completion by Participant

Time Frame: Up to 8 weeks

Feasibility of the treatment as measured through number of randomized participants who completed all 4 telephone sessions.

Acceptability Measured Using the Client Satisfaction Questionnaire (CSQ-8)

Time Frame: Up to 8 weeks

Acceptability was measured through the median score on a validated acceptability measure. Item responses run on a scale of 1 to 4, with a total score range of 8-32. Higher scores indicate higher satisfaction with the service (acceptability). A median score of 28 or higher is considered acceptable. This measure was collected for both patients and partners.

Secondary Outcomes

  • Change in Sexual Function Measured Using the Female Sexual Function Index (FSFI)(Baseline to up to 8 weeks)
  • Change in Sexual Function Measured Using the International Index of Erectile Function(Baseline to up to 8 weeks)
  • Change in Sexual Satisfaction Measured Using the Patient-Reported-Outcomes Measurement Information System (PROMIS) Sexual Satisfaction Items(Baseline to up to 8 weeks)
  • Change in Sexual Distress Measured Using the Female Sexual Distress Scale-Revised(Baseline to up to 8 weeks)
  • Change in Beliefs (Self-efficacy)(Baseline to up to 8 weeks)
  • Change in Sexual Communication Measured Using the Dyadic Sexual Communication Scale(Baseline to up to 8 weeks)
  • Change in Relationship Quality Measured Using the Dyadic Adjustment Scale-7 Item(Baseline to up to 8 weeks)
  • Change in Body Image Distress Measured Using the Body Image Scale(Baseline to up to 8 weeks)
  • Change in Depression Measured Using the Patient Health Questionnaire-9 Item(Baseline to up to 8 weeks)
  • Change in Emotional Intimacy Measured Using the Personal Assessment of Intimacy in Relationships (PAIR) Emotional Intimacy Scale(Baseline to up to 8 weeks)
  • Change in Anxiety Measured Using the Generalized Anxiety Disorder 7-item(Baseline to up to 8 weeks)
  • Change in Cancer-related Distress Using the Impact of Events Scale-Revised(Baseline to up to 8 weeks)

Study Sites (1)

Loading locations...

Similar Trials